Sign in

Lost your password?
(close)

China

China / Hong Chow Leaves Roche for Big New Role at Merck

In a big career move on a personal level and a sign of China’s continuing significance to global pharma, Hong Chow has left her role as General Manager for Roche…

China / First CAR-T Approval; AZ & Bayer Take VBP Hit; Lonza Boosts Manufacturing Capacity

The latest news from Chinese pharma, including a historic first approval for Fosun Kite’s CAR-T therapy Yescarta;…

China / Sinopharm Tops Brand Value Rankings; Simcere Splashes $565M on Alzheimer’s Drug; Innovent-Ascentage Tie-Up A Sign of Biotech Deals to Come?

The latest news from the Chinese pharmaceutical industry, including recent deals between domestic pharma giant…

China / Fosun-Kite Yescarta Approval Signals Beginning of CAR-T Era

A historic approval for Fosun-Kite’s CAR-T therapy Yescarta in China looks set to pave the way for further…

In Conversation

Dun Yang – President & CEO, Anticancer Bioscience

Anticancer Bioscience is an exciting international precision oncology company, applying synthetic lethal approaches to develop targeted cancer therapies. President & CEO Dun Yang explains the company’s origins, how ACB’s approach differs from that of its competitors, and how he plans to make the firm into “China’s Genentech.”   We want to be the prime example of an innovative, science-driven biotech…

Sizhen Wang – CEO & Co-Founder, Genetron Health

Hong Chow Leaves Roche China for Big New Role at Merck

China / Hong Chow Leaves Roche for Big New Role at Merck

In a big career move on a personal level and a sign of China’s continuing significance to global pharma, Hong…

Related Report

China / New Country President for MSD Amid Changes at HQ & Access Challenges

MSD, which has had a presence in China since 1990, recently appointed Belgian national Anna van Acker to lead its…

China / Roche Hoping to Spearhead ‘Created in China’ Push with New Innovation Accelerator

In May 2021 Swiss giant Roche launched the ‘Roche Accelerator’ in Shanghai, a USD 31.1 million investment…

China / BioNTech-Fosun JV; Patent Law Revamp; Hong Kong as a Biotech Listing Hub

The latest news from Chinese pharma, including an overhaul of the country’s patent law; a BioNTech-Fosun tie-up…

China / EpimAb Looks to 2022 IPO & Global Leadership in Bispecific Antibodies

Hot on the heels of a USD 120 million fundraising round, Shanghai-based EpimAb Biotherapeutics is now looking…

We use cookies to ensure that we give you the best experience on our site. For more info click here